全文获取类型
收费全文 | 110480篇 |
免费 | 8692篇 |
国内免费 | 3209篇 |
专业分类
耳鼻咽喉 | 1151篇 |
儿科学 | 1650篇 |
妇产科学 | 1475篇 |
基础医学 | 8474篇 |
口腔科学 | 1880篇 |
临床医学 | 11762篇 |
内科学 | 12029篇 |
皮肤病学 | 1007篇 |
神经病学 | 6198篇 |
特种医学 | 2658篇 |
外国民族医学 | 17篇 |
外科学 | 12729篇 |
综合类 | 20958篇 |
现状与发展 | 10篇 |
一般理论 | 5篇 |
预防医学 | 9485篇 |
眼科学 | 2188篇 |
药学 | 8971篇 |
213篇 | |
中国医学 | 15980篇 |
肿瘤学 | 3541篇 |
出版年
2024年 | 173篇 |
2023年 | 1967篇 |
2022年 | 2989篇 |
2021年 | 4940篇 |
2020年 | 4796篇 |
2019年 | 4316篇 |
2018年 | 4051篇 |
2017年 | 4101篇 |
2016年 | 4200篇 |
2015年 | 3756篇 |
2014年 | 8073篇 |
2013年 | 7356篇 |
2012年 | 7179篇 |
2011年 | 8129篇 |
2010年 | 6933篇 |
2009年 | 5383篇 |
2008年 | 4879篇 |
2007年 | 5172篇 |
2006年 | 4572篇 |
2005年 | 4020篇 |
2004年 | 3191篇 |
2003年 | 2913篇 |
2002年 | 2124篇 |
2001年 | 1964篇 |
2000年 | 1564篇 |
1999年 | 1317篇 |
1998年 | 958篇 |
1997年 | 907篇 |
1996年 | 797篇 |
1995年 | 910篇 |
1994年 | 828篇 |
1993年 | 601篇 |
1992年 | 567篇 |
1991年 | 480篇 |
1990年 | 404篇 |
1989年 | 377篇 |
1988年 | 361篇 |
1987年 | 313篇 |
1986年 | 298篇 |
1985年 | 579篇 |
1984年 | 548篇 |
1983年 | 430篇 |
1982年 | 476篇 |
1981年 | 437篇 |
1980年 | 430篇 |
1979年 | 354篇 |
1978年 | 312篇 |
1977年 | 270篇 |
1976年 | 212篇 |
1974年 | 121篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
目的 评价多功能套针浮刺疗法对神经根型颈椎病的临床疗效。方法 选取256例神经根型颈椎病患者,按随机数字表法分为观察组与对照组各128例。观察组应用多功能套针浮刺疗法进行干预,对照组为常规针刺治疗。两组患者均治疗7天。分别于治疗前后观察两组患者的简化McGill疼痛问卷(SF-MPQ)、国际标准颈椎功能障碍指数(NDI)和田中靖久颈椎病症状20分法量表评分,并于治疗结束后3个月观察复发率。结果 两组患者治疗后的SF-MPQ量表评分、NDI量表评分及田中靖久颈椎病症状20分法评分与治疗前相比均有改善(P<0.05),且观察组优于对照组(P<0.05);两组患者于治疗后3个月随访,SF-MPQ量表评分与治疗后相比均有改善,且观察组优于对照组(P<0.05);观察组临床疗效总有效率为96.88%,愈显率为81.25%;对照组总有效率为78.13%,愈显率为46.88%,观察组优于对照组(P<0.05)。结论 应用多功能套针浮刺疗法治疗神经根型颈椎病临床疗效显著,见效较快,可有效降低其复发率,且作用稳定,效果持久,值得临床推广应用。 相似文献
3.
4.
5.
6.
7.
目的 基于红外热成像技术探讨“扶正温阳法”对阳虚质的影响,探讨阳虚质者红外热图的共性规律,分析判断“扶正温阳法”干预阳虚质人群的疗效。方法 纳入30例阳虚质患者给予益气温阳药物在大椎、肾俞(双侧)、命门等进行穴位贴敷,分别在干预前后运用红外热成像技术测定督脉、腰部、腹部、双手及双足局部温度的变化。结果 干预后阳虚体质患者的督脉、腰部、腹部、双手、双足温度均升高(P<0.05),阳虚体质局部温度得以改善。结论 本研究发现“扶正温阳法”可诱发循经热传导现象,通过调节热能代谢而起到调治阳虚体质的作用,红外热成像技术可用来辅助评价阳虚质的治疗效果,对临床指导制定阳虚质人群的干预方案疗效判定具有指导意义。 相似文献
8.
9.
《Journal of vascular and interventional radiology : JVIR》2022,33(9):1034-1044.e29
PurposeTo assess the safety and tolerability of a vandetanib-eluting radiopaque embolic (BTG-002814) for transarterial chemoembolization (TACE) in patients with resectable liver malignancies.Materials and MethodsThe VEROnA clinical trial was a first-in-human, phase 0, single-arm, window-of-opportunity study. Eligible patients were aged ≥18 years and had resectable hepatocellular carcinoma (HCC) (Child-Pugh A) or metastatic colorectal cancer (mCRC). Patients received 1 mL of BTG-002814 transarterially (containing 100 mg of vandetanib) 7–21 days prior to surgery. The primary objectives were to establish the safety and tolerability of BTG-002814 and determine the concentrations of vandetanib and the N-desmethyl vandetanib metabolite in the plasma and resected liver after treatment. Biomarker studies included circulating proangiogenic factors, perfusion computed tomography, and dynamic contrast-enhanced magnetic resonance imaging.ResultsEight patients were enrolled: 2 with HCC and 6 with mCRC. There was 1 grade 3 adverse event (AE) before surgery and 18 after surgery; 6 AEs were deemed to be related to BTG-002814. Surgical resection was not delayed. Vandetanib was present in the plasma of all patients 12 days after treatment, with a mean maximum concentration of 24.3 ng/mL (standard deviation ± 13.94 ng/mL), and in resected liver tissue up to 32 days after treatment (441–404,000 ng/g). The median percentage of tumor necrosis was 92.5% (range, 5%–100%). There were no significant changes in perfusion imaging parameters after TACE.ConclusionsBTG-002814 has an acceptable safety profile in patients before surgery. The presence of vandetanib in the tumor specimens up to 32 days after treatment suggests sustained anticancer activity, while the low vandetanib levels in the plasma suggest minimal release into the systemic circulation. Further evaluation of this TACE combination is warranted in dose-finding and efficacy studies. 相似文献
10.
BackgroundPrior to dolutegravir availability, ritonavir-boosted lopinavir (LPV/r) was an alternative recommendation when first-line drugs could not be used. A high concentration of protease inhibitors was observed in the Thai people living with HIV (PLWH). Thus, dose reduction of LPV/r may be possible. However, the pharmacokinetics and dose optimization of LPV/r have never been investigated. This study aimed to develop a population pharmacokinetic model of LPV/r and provide dosage optimization in Thai PLWH.MethodsLPV and RTV trough concentrations from Thai PLWH were combined with intensive data. The data were analyzed by the nonlinear mixed-effects modeling approach. The influence of RTV concentration on LPV oral clearance (CL/F) was investigated.ResultsRifampicin (RIF) use increased LPV and RTV CL/F by 2.16-fold and 1.99-fold, respectively. The reduced dose of 300/75 and 200/150 mg twice daily provided a comparable percentage of patients achieving LPV target trough concentration to the standard dose for PI-naïve patients. For HIV/TB co-infected patients receiving RIF who could not tolerate the recommended dose, the reduced dose of 600/150 mg twice daily was recommended.ConclusionThe population pharmacokinetic model was developed by integrating the interaction between LPV and RTV. The reduced LPV/r dosage offers sufficient LPV exposure for Thai PLWH. 相似文献